Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
US12128101B2 · kind B2 · utility
1Cited by
58References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2018 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Nov 18, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.